Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 442

1.

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL).

Okamoto M, Kusumoto S.

Int J Hematol. 2020 Jan;111(1):5-15. doi: 10.1007/s12185-019-02784-x. Epub 2019 Dec 10. No abstract available.

PMID:
31823126
2.

[Richter syndrome successfully treated with ibrutinib monotherapy: two case reports].

Fujinami H, Kusumoto S, Masaki A, Ohshima Y, Tachita T, Sasaki H, Marumo Y, Yoshida T, Narita T, Ito A, Ri M, Komatsu H, Inagaki H, Iida S.

Rinsho Ketsueki. 2019;60(10):1462-1467. doi: 10.11406/rinketsu.60.1462. Japanese.

PMID:
31695008
3.

[Research achievements and questions on hepatitis B virus reactivation in hematological diseases].

Mizokami M, Kusumoto S.

Rinsho Ketsueki. 2019;60(9):1401-1407. doi: 10.11406/rinketsu.60.1401. Review. Japanese.

PMID:
31597870
4.

CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.

Sakamoto Y, Fujii K, Murase S, Nakano S, Masaki A, Murase T, Kusumoto S, Iida S, Utsunomiya A, Ueda R, Ishida T, Inagaki H.

Int J Hematol. 2019 Oct;110(4):389-392. doi: 10.1007/s12185-019-02728-5. Epub 2019 Aug 29.

PMID:
31468320
5.

Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.

Yamaoka T, Arata S, Homma M, Homma T, Kusumoto S, Ando K, Manabe R, Kishino Y, Ohba M, Tsurutani J, Takimoto M, Ohmori T, Sagara H.

Int J Mol Sci. 2019 Aug 17;20(16). pii: E4021. doi: 10.3390/ijms20164021.

6.

Cleavage of Si-H, B-H, and C-H Bonds by Metal-Ligand Cooperation.

Higashi T, Kusumoto S, Nozaki K.

Chem Rev. 2019 Sep 25;119(18):10393-10402. doi: 10.1021/acs.chemrev.9b00262. Epub 2019 Aug 13.

PMID:
31408323
7.

Comparison of three frailty models and a sarcopenia model in elderly patients with chronic obstructive pulmonary disease.

Hirai K, Tanaka A, Homma T, Kaneko K, Uno T, Sato H, Manabe R, Ohta S, Kusumoto S, Yamaguchi F, Suzuki S, Sagara H.

Geriatr Gerontol Int. 2019 Sep;19(9):896-901. doi: 10.1111/ggi.13740. Epub 2019 Jul 15.

PMID:
31309700
8.

Depressive symptoms during the first month of chemotherapy and survival in patients with hematological malignancies: A prospective cohort study.

Hasegawa T, Okuyama T, Uchida M, Aiki S, Imai F, Nishioka M, Suzuki N, Iida S, Komatsu H, Kusumoto S, Ri M, Osaga S, Akechi T.

Psychooncology. 2019 Aug;28(8):1687-1694. doi: 10.1002/pon.5143. Epub 2019 Jul 2.

PMID:
31267595
9.

Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.

Yoshida T, Ri M, Fujinami H, Oshima Y, Tachita T, Marumo Y, Sasaki H, Kinoshita S, Totani H, Narita T, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.

Int J Hematol. 2019 Aug;110(2):228-236. doi: 10.1007/s12185-019-02669-z. Epub 2019 May 22.

PMID:
31119611
10.

Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma.

Ashour R, Ri M, Aly SS, Yoshida T, Tachita T, Kanamori T, Aoki S, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Komatsu H, Mansour S, Elsaied AA, Iida S.

Int J Hematol. 2019 Jul;110(1):69-76. doi: 10.1007/s12185-019-02649-3. Epub 2019 May 21.

PMID:
31115879
11.

Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.

Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Hiura M, Takahashi T, Morita A, Inagaki H, Iida S, Ishida T.

Clin Cancer Res. 2019 Jul 15;25(14):4388-4399. doi: 10.1158/1078-0432.CCR-18-2575. Epub 2019 Apr 24.

PMID:
31018922
12.

Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole.

Yoshida T, Tachita T, Fujinami H, Oshima Y, Sasaki H, Marumo Y, Narita T, Ito A, Ri M, Kusumoto S, Ishida T, Komatsu H, Iida S.

Intern Med. 2019 Aug 1;58(15):2219-2224. doi: 10.2169/internalmedicine.2082-18. Epub 2019 Apr 17.

13.

Weak ferromagnetism derived from spin canting in an amido-bridged homochiral Mn(iii) 1-D coordination polymer.

Kusumoto S, Koga A, Kobayashi F, Ohtani R, Kim Y, Lindoy LF, Hayami S, Nakamura M.

Dalton Trans. 2019 Jun 28;48(24):8617-8622. doi: 10.1039/c9dt00593e. Epub 2019 Apr 3.

PMID:
30942224
14.

Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.

Sasaki H, Mitani S, Kusumoto S, Marumo Y, Asano A, Yoshida T, Narita T, Ito A, Yano H, Ri M, Ishida T, Komatsu H, Iida S.

Int J Hematol. 2019 Jul;110(1):119-123. doi: 10.1007/s12185-019-02628-8. Epub 2019 Mar 16.

PMID:
30879266
15.

Beneficial Effect of Early Intervention with Garenoxacin for Bacterial Infection-Induced Acute Exacerbation of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.

Homma T, Kawahara T, Mikuni H, Uno T, Sato H, Fujiwara A, Uchida Y, Fukuda Y, Manabe R, Ida H, Kuwahara N, Kimura T, Hirai K, Miyata Y, Jinno M, Yamaguchi M, Kishino Y, Murata Y, Ohta S, Yamamoto M, Watanabe Y, Yamaguchi H, Kusumoto S, Suzuki S, Tanaka A, Yokoe T, Ohnishi T, Sagara H.

Int Arch Allergy Immunol. 2019;178(4):355-362. doi: 10.1159/000495761. Epub 2019 Feb 13.

PMID:
30759444
16.

Metal-Ligand Cooperative C-H Bond Formation by Cyclopentadienone Platinum Complexes.

Higashi T, Ando H, Kusumoto S, Nozaki K.

J Am Chem Soc. 2019 Feb 13;141(6):2247-2250. doi: 10.1021/jacs.8b13829. Epub 2019 Feb 5.

PMID:
30702878
17.

Receptor Tyrosine Kinase-Targeted Cancer Therapy.

Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T.

Int J Mol Sci. 2018 Nov 6;19(11). pii: E3491. doi: 10.3390/ijms19113491. Review.

18.

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K.

Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.

19.

KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.

Nakatani K, Yamaoka T, Ohba M, Fujita KI, Arata S, Kusumoto S, Taki-Takemoto I, Kamei D, Iwai S, Tsurutani J, Ohmori T.

Mol Cancer Ther. 2019 Jan;18(1):112-126. doi: 10.1158/1535-7163.MCT-18-0591. Epub 2018 Oct 15.

20.

[Treatment strategy for newly diagnosed Hodgkin lymphoma: current evidence].

Kusumoto S.

Rinsho Ketsueki. 2018;59(10):2117-2126. doi: 10.11406/rinketsu.59.2117. Review. Japanese.

PMID:
30305517
21.

Wheel-type heterometallic ferromagnetic clusters: [Ni7-xMx(HL)63-OMe)43-OH)2]Cl2 (M = Zn, Co, Mn; x = 1, 3).

Kobayashi F, Ohtani R, Kusumoto S, Lindoy LF, Hayami S, Nakamura M.

Dalton Trans. 2018 Nov 27;47(46):16422-16428. doi: 10.1039/c8dt03275k.

PMID:
30280733
22.

Effect of glutamine on lymphoplasmacytic lymphoma, especially on the viewpoint of the differentiation into vulnerable subpopulation.

Wada N, Nojima S, Tahara SI, Ohshima K, Kurashige M, Kawasaki K, Tone M, Kusumoto S, Ikeda JI, Morii E.

Pathol Res Pract. 2018 Oct;214(10):1667-1674. doi: 10.1016/j.prp.2018.08.019. Epub 2018 Aug 27.

PMID:
30173943
23.

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma.

Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S.

Haematologica. 2018 Dec;103(12):2059-2068. doi: 10.3324/haematol.2018.191395. Epub 2018 Aug 3.

24.

Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer.

Izumida K, Kaneko A, Takahashi K, Kusumoto S, Narita T, Takami A, Iida S, Aoyagi K, Tanaka Y.

Hepatol Res. 2018 Dec;48(13):1081-1091. doi: 10.1111/hepr.13229. Epub 2018 Aug 26.

PMID:
30006955
25.

Creating capsules with cubanes.

Kusumoto S, Kobayashi F, Ohtani R, Zhang Y, Harrowfield J, Kim Y, Hayami S, Nakamura M.

Dalton Trans. 2018 Jul 24;47(29):9575-9578. doi: 10.1039/c8dt01911h.

PMID:
29972168
26.

CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.

Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, Tokunaga M, Utsunomiya A, Ito A, Kusumoto S, Iida S, Ueda R, Inagaki H.

Blood. 2018 Aug 16;132(7):758-761. doi: 10.1182/blood-2018-02-835991. Epub 2018 Jun 21. No abstract available.

PMID:
29930010
27.

Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.

Kinoshita S, Ri M, Kanamori T, Aoki S, Yoshida T, Narita T, Totani H, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.

Oncol Lett. 2018 Jun;15(6):9450-9456. doi: 10.3892/ol.2018.8501. Epub 2018 Apr 16.

28.

Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals.

Masaki A, Ishida T, Suzuki S, Ito A, Narita T, Kinoshita S, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Iida S.

Cancer Sci. 2018 Aug;109(8):2383-2390. doi: 10.1111/cas.13654. Epub 2018 Jun 27.

29.

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.

Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.

PLoS One. 2018 May 8;13(5):e0196780. doi: 10.1371/journal.pone.0196780. eCollection 2018.

30.

Successful radiotherapy for endometrial serous carcinoma with local repeated recurrence.

Kusumoto S, Fujiwara H, Sagawa M, Nobuzane T, Nishida T, Akagi Y, Hirokawa Y, Katsube Y.

Int Cancer Conf J. 2018 Apr 5;7(2):71-75. doi: 10.1007/s13691-018-0323-4. eCollection 2018 Apr.

31.

Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits.

Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S.

Oncotarget. 2018 Jan 11;9(11):9975-9991. doi: 10.18632/oncotarget.24160. eCollection 2018 Feb 9.

32.

[Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance mimicking POEMS syndrome].

Kanamori T, Kusumoto S, Okita K, Hagiwara S, Kato C, Nakashima T, Murakami S, Narita T, Ito A, Ri M, Ishida T, Komatsu H, Matsukawa N, Iida S.

Rinsho Ketsueki. 2018;59(2):161-166. doi: 10.11406/rinketsu.59.161. Japanese.

PMID:
29515067
33.

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K.

Cancer Sci. 2018 May;109(5):1552-1561. doi: 10.1111/cas.13550. Epub 2018 Apr 17.

34.

Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors.

Aiki S, Okuyama T, Sugano K, Kubota Y, Imai F, Nishioka M, Ito Y, Iida S, Komatsu H, Ishida T, Kusumoto S, Akechi T.

Jpn J Clin Oncol. 2018 Jan 1;48(1):61-67. doi: 10.1093/jjco/hyx159.

PMID:
29136185
35.

Clinical significance of tryptophan catabolism in Hodgkin lymphoma.

Masaki A, Ishida T, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S.

Cancer Sci. 2018 Jan;109(1):74-83. doi: 10.1111/cas.13432. Epub 2017 Nov 29.

36.

JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 3. Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).

Takeuchi J, Kusumoto S, Akiyama H, Kanda Y, Izutsu K.

Int J Hematol. 2017 Dec;106(6):732-747. doi: 10.1007/s12185-017-2350-x. Epub 2017 Oct 24. No abstract available.

PMID:
29067593
37.

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.

Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Imada K, Tanaka Y, Takaori-Kondo A, Inagaki H, Scholz A, Lienau P, Kuroda T, Ueda R, Iida S.

Blood. 2017 Aug 31;130(9):1114-1124. doi: 10.1182/blood-2016-09-741983. Epub 2017 Jun 23.

PMID:
28646117
38.

Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.

Iida S, Suzuki K, Kusumoto S, Ri M, Tsukada N, Abe Y, Aoki M, Inagaki M.

Int J Hematol. 2017 Oct;106(4):541-551. doi: 10.1007/s12185-017-2281-6. Epub 2017 Jun 22.

PMID:
28643017
39.

[Clinical Study to Determine the Dose Intensity of BEP Chemotherapy for Ovarian Malignant Germ Cell Tumors].

Kusumoto S, Naito H, Imazu K, Kai I, Hamasaki A, Kazusa Y, Nakashima Y, Kodama M, Kumagai M, Ueda K.

Gan To Kagaku Ryoho. 2017 Mar;44(3):255-259. Japanese.

PMID:
28292998
40.

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.

Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, Ando K, Ishida H, Ohnishi T, Sasaki Y.

Mol Cancer Res. 2017 Jul;15(7):915-928. doi: 10.1158/1541-7786.MCR-16-0482. Epub 2017 Mar 13.

41.

Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay.

Shinkai N, Kusumoto S, Murakami S, Ogawa S, Ri M, Matsui T, Tamori A, Toyoda H, Ishida T, Iida S, Tanaka Y.

Liver Int. 2017 Aug;37(8):1138-1147. doi: 10.1111/liv.13349. Epub 2017 Jan 29.

PMID:
27992664
42.

Gated Photochromic System of Diarylethene with a Photon-Working Key.

Mahvidi S, Takeuchi S, Kusumoto S, Sato H, Nakagawa T, Yokoyama Y.

Org Lett. 2016 Oct 7;18(19):5042-5045. Epub 2016 Sep 23.

PMID:
27662504
43.

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.

Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y.

Mol Cancer Ther. 2016 Dec;15(12):3040-3054. Epub 2016 Sep 9.

44.

Guillain-Barré syndrome after allogeneic bone marrow transplantation: Case report and literature review.

Yoshida T, Ueki Y, Suzuki T, Kawagashira Y, Koike H, Kusumoto S, Ida S, Oguri T, Omura M, Sobue, Matsukawa N.

eNeurologicalSci. 2016 Aug 4;4:52-55. doi: 10.1016/j.ensci.2016.08.001. eCollection 2016 Sep.

45.

Does cognitive decline decrease health utility value in older adult patients with cancer?

Akechi T, Aiki S, Sugano K, Uchida M, Yamada A, Komatsu H, Ishida T, Kusumoto S, Iida S, Okuyama T.

Psychogeriatrics. 2017 May;17(3):149-154. doi: 10.1111/psyg.12205. Epub 2016 Jul 13.

46.

The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy.

Totani H, Kusumoto S, Tanaka Y, Suzuki N, Hagiwara S, Kinoshita S, Iio E, Ito A, Ri M, Ishida T, Komatsu H, Iida S.

Int J Hematol. 2016 Sep;104(3):384-91. doi: 10.1007/s12185-016-2033-z. Epub 2016 Jun 2.

PMID:
27255233
47.

[Outcomes of Tertiary Debulking Surgery(TDS)for Re-Recurrent Ovarian Cancer].

Kusumoto S, Konishi H, Okame S, Komatsu M, Shiroyama Y, Yokoyama T, Takehara K.

Gan To Kagaku Ryoho. 2016 Mar;43(3):357-60. Japanese.

PMID:
27067855
48.

Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.

Hirose T, Fujita K, Kusumoto S, Oki Y, Murata Y, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohmori T, Sasaki Y.

Lung Cancer. 2016 Mar;93:69-76. doi: 10.1016/j.lungcan.2016.01.005. Epub 2016 Jan 11.

PMID:
26898617
49.

Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies.

Mochida S, Nakao M, Nakayama N, Uchida Y, Nagoshi S, Ido A, Mimura T, Harigai M, Kaneko H, Kobayashi H, Tsuchida T, Suzuki H, Ura N, Nakamura Y, Bessho M, Dan K, Kusumoto S, Sasaki Y, Fujii H, Suzuki F, Ikeda K, Yamamoto K, Takikawa H, Tsubouchi H, Mizokami M.

J Gastroenterol. 2016 Oct;51(10):999-1010. doi: 10.1007/s00535-016-1168-2. Epub 2016 Feb 1.

PMID:
26831356
50.

Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

Totani H, Ri M, Kato C, Nakashima T, Suzuki N, Hagiwara S, Kanamori T, Murakami S, Masuda A, Kinoshita S, Yoshida T, Narita T, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.

Int J Hematol. 2016 Mar;103(3):316-21. doi: 10.1007/s12185-015-1925-7. Epub 2015 Dec 29.

PMID:
26715148

Supplemental Content

Loading ...
Support Center